Balancing act: Tapering mycophenolate mofetil in immune checkpoint inhibitor hepatitis-strategies, outcomes, and risks
While MMF is effective in managing ICI hepatitis, tapering remains a clinical challenge with potential risks of hepatitis flare and disease progression. Standardized tapering protocols are needed to optimize immunosuppression while preserving anticancer efficacy. Future studies should focus on biomarker-driven tapering strategies and prospective trials to establish best practices.
Authors
- Andrew M. Moon (ORCID: https://orcid.org/0000-0001-7163-2062)
- Anuroop Yekula
- Sahaj Mujumdar
- Dahlia Weinberg
- Mark Levstik
- Shu‐Yen Chan (ORCID: https://orcid.org/0000-0002-8453-9892)
- Patrick Twohig (ORCID: https://orcid.org/0000-0002-5423-8749)
- Sofia D. Shaikh (ORCID: https://orcid.org/0000-0003-2015-3402)
- Nida Ansari
- Stuart McPherson (ORCID: https://orcid.org/0000-0002-5638-2453)
- David Jerez Diaz
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Rochester Medical Center (US)
- Sarasota Memorial Hospital (US)
- University of North Carolina Hospitals (US)
- St. Joseph’s University Medical Center (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- World Journal of Gastrointestinal Pharmacology and Therapeutics
- Published
- 2025-12-05
- DOI
- https://doi.org/10.4292/wjgpt.v16.i4.109485
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00